Adial Pharmaceuticals (ADIL) Soars 12.23% on AD04 Production Advancements

Adial Pharmaceuticals (ADIL) has surged 12.23% in pre-market trading on June 25, 2025, driven by significant advancements in the production of its flagship drug, AD04, aimed at treating Alcohol Use Disorder (AUD).

Adial Pharmaceuticals has recently executed key agreements with Thermo Fisher Scientific and Cambrex to produce AD04, a genetically targeted therapy focusing on serotonin-3 receptor antagonism. These partnerships are crucial for finalizing upcoming clinical trials and preparing a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).

The collaboration has already resulted in the completion of essential demonstration batches, a critical step before proceeding to registration and clinical batches. The agreements cover all necessary manufacturing stages for both the clinical studies of AD04 and the Chemistry, Manufacturing, and Controls documentation needed for the NDA submission.

These developments mark a pivotal phase in Adial Pharmaceuticals' efforts to bring a new treatment option for AUD to the market, potentially driving investor confidence and stock performance.